Počet záznamů: 1
Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response
- 1.Adkins, I. - Sadílková, I. - Hradilová, N. - Tomala, Jakub - Tomalová, Barbora - Kovář, Marek - Mikysková, R. - Reiniš, Milan - de Martynoff, G. - Bechard, D. - Moebius, U. - Spíšek, R.
Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response.
Cancer Research. American Association for Cancer Research. Roč. 78, 13 S (2018). ISSN 0008-5472. E-ISSN 1538-7445.
[Annual Meeting of the American-Association-for-Cancer-Research (AACR). 14.04.2018-18.04.2018]
Obor OECD: Microbiology
DOI: https://doi.org/10.1158/1538-7445.AM2018-3775
http://hdl.handle.net/11104/0305937
Počet záznamů: 1